Middle East and Africa Blood Coagulants Market is Expected to Grow at a CAGR of ~9.5% By 2023

Market Research Future has a cooked research report on MEA blood coagulants market. Which is Expected to Grow at a CAGR of ~9.5% By 2023

Middle East & Africa Blood Coagulants Market Information: By Types (Coagulation Factor (Recombinant Coagulation Factor, Plasma Derived Recombinant Coagulation Factor)), Indication (Haemophilia, Surgery, other Bleeding Disorders) –Forecast Till 2023

The MEA blood coagulants market is growing continuously and expected to grow at a CAGR of 9.5% from 2017 to 2023
The burden of bleeding disorder is rapidly increasing across the globe. Developing and under developed countries are increasingly falling for bleeding disorders in the Middle East and African region. Based on the prevalence rate, hemophilia and Von Willebrand disease (VWD) are the most common bleeding disorders in the Middle East and Africa. Increasing prevalence of bleeding disorders likely to drive the growth of the market. The developing countries are providing various opportunities to the healthcare organization to come up with new affordable drugs.

Get a Sample report at https://www.marketresearchfuture.com/sample_request/2743 .

Major Players in Bronchoscopes Market
Some of the major players in this market are Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).
The economic outlook of high income countries in the Middle East region such as Saudi Arabia, the UAE, and others is improving and is expected to support the recovery in the region. Moreover, Ministry of Health (MOH) and various other government bodies are allocating large pool of funds and coordinating health promotion programs in Saudi Arabia.
Additionally, surge in the population of Saudi Arabia strongly contributes to the increasing demand for the healthcare facilities.
Regional Analysis
MEA blood coagulants market is consist of the Middle East & African countries.
Saudi Arabia (KSA, dominates the MEA blood coagulants market with nearly 21.1% share of the Middle East & African market.
In spite of increasing demand for the treatment, the R&D sector of the Middle East and African region is not developed enough to address the upcoming health challenges.
In Saudi Arabia, the pharmaceutical industry is characterized by domestic manufacturing base and licensing agreements with branded research-based drug manufacturing firms. Moreover, the government policies are biased for domestic producers by providing them various exemptions such as, interest-free funding, neglecting import duties on raw materials, and subsidized utility charges
According to a study published in the Journal for Clinical Studies in 2014, no legal framework describing rare diseases and orphan drug research & development is present in the Middle East Countries such as Saudi Arabia, Jordan, Lebanon, and Egypt. In one of the Middle East countries, the UAE, a Biotechnology and Research Park, named as DuBiotech, has been established for improving R&D status, and to collaborate with local companies.
African region is also dependent on imported medicines and other health technologies.

Get a discount at https://www.marketresearchfuture.com/check-discount/2743

Key Findings:
• Hemophilia segment dominates the market with nearly 45.5% share of the MEA market
• MEA blood coagulation market is projected to reach about USD 141.68 million by 2023
• MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016
• UAE is the fastest growing region in the MEA market and projected to grow at a CAGR of 10.1% during forecast period
Segmentation
The MEA blood coagulants market is segmented on the basis of types, indications, and by country.
On the basis of types, the market is segmented into coagulation factor and others. The coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.
On the basis of indication, the market is segmented into hemophilia, surgery, other bleeding disorders, and others. The hemophilia is further divided into hemophilia A and hemophilia B. On the basis of country, the market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of the Middle East & Africa

Browse Complete Report at https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743 .

Table Of Contents

1 Introduction

2 Research Methodology

3 Market Dynamics

4 Market Factor Analysis
Continue..

About us
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com
Web: Https://Www.Marketresearchfuture.Com

This release was published on openPR.